){kind=logo}
Loeb & Loeb LLP is proud to sponsor the American Conference Institute's 8th Annual Summit on Biosimilars where partner Mark Waddell will be speaking on a panel titled, "Policy and Politics of Biosimilars under the New Administration."
From conference website:
With FDA approval of three additional biosimilars, 2016 was a tremendous year for the industry, forecasting a healthy and robust future for the biosimilars market. Experts expect the global biosimilars market to more than triple to a value of $11 Billion by 2021. With four biosimilars now approved in the U.S. and many more applications currently before the FDA, the business of biosimilars is booming and there has never been a more critical time to hear insider insights from industry authorities on the status of the biosimilars business today, and to discuss strategies with your peers on what the next steps are given the potential changes with the new administration.
For more information, including how to register, please visit the conference website.
From conference website:
With FDA approval of three additional biosimilars, 2016 was a tremendous year for the industry, forecasting a healthy and robust future for the biosimilars market. Experts expect the global biosimilars market to more than triple to a value of $11 Billion by 2021. With four biosimilars now approved in the U.S. and many more applications currently before the FDA, the business of biosimilars is booming and there has never been a more critical time to hear insider insights from industry authorities on the status of the biosimilars business today, and to discuss strategies with your peers on what the next steps are given the potential changes with the new administration.
For more information, including how to register, please visit the conference website.
-
Chair, Patent Litigation ＆ Counseling